2024
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
Barragan-Carrillo R, Chawla N, Salgia N, Meza L, Zengin Z, Li X, Dizman N, Ebrahimi H, Hsu J, Castro D, Mercier B, Dorff T, Tripathi A, Bergerot C, Bergerot P, Chehrazi-Raffle A, Pal S. Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: tps491-tps491. DOI: 10.1200/jco.2024.42.4_suppl.tps491.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitionBaseline to weekFirst-line treatmentClinical responsePoor-risk metastatic renal cell carcinomaFirst-line treatment of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaCombination of immune checkpoint inhibitionEfficacy of anti-PD1 therapyCombination immune checkpoint inhibitionDual immune checkpoint inhibitionCD8+ T cellsAnti-PD1 therapyImmune-related toxicitiesProgression-free survivalWeeks of therapyReduced tumor sizeTyrosine kinase inhibitorsSingle-center trialRenal cell carcinomaClear-cell RCCMouse tumor modelsOne-sided type I errorCombination nivolumab
2023
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
Ebrahimi H, Meza L, Lee K, Malhotra J, Alcantara M, Zengin Z, Dizman N, Govindarajan A, Hsu J, Llamas-Quitiquit M, Chawla N, Castro D, Mercier B, Liu S, Chehrazi-Raffle A, Dorff T, Frankel P, Li X, Pal S, Tripathi A. Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial. Journal Of Clinical Oncology 2023, 41: lba104-lba104. DOI: 10.1200/jco.2023.41.17_suppl.lba104.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalTyrosine kinase inhibitorsPrimary endpointClinical outcomesStool specimensDual immune checkpoint inhibitorsMedian progression-free survivalImproved progression-free survivalOne-sided type I errorBifidobacterium sppGrade 3/4 toxicitiesImmune checkpoint inhibitorsStudy's primary endpointWeeks of treatmentDose/scheduleRandomized clinical trialsRenal cell carcinomaEligible ptsPo bidSystemic immunomodulationCheckpoint inhibitorsSecondary endpointsLine therapyMetastatic disease
2021
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Gan C, Wells J, Schmidt A, Powles T, Tran B, Meza L, Labaki C, Lee J, Wood L, Shapiro J, Ernst D, Kapoor A, Canil C, Yuasa T, McKay R, Beuselinck B, Donskov F, Dudani S, Choueiri T, Heng D. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2021, 39: 4554-4554. DOI: 10.1200/jco.2021.39.15_suppl.4554.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaIpi-nivoOverall survivalCell histologyInternational mRCC Database Consortium criteriaOutcomes of first-lineTreatment durationNon-clear cell histologyPoor-risk diseaseTyrosine kinase inhibitorsRenal cell carcinomaRisk categoriesMedian OSBrain metastasesBone metastasesLiver metastasesPoor riskRisk diseaseCell carcinomaFirst-lineMedian ageProgressive diseaseMedian TDNeutrophil count